INKT
Income statement / Annual
Last year (2025), MiNK Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, MiNK Therapeutics Inc's net income was -$12.49 M.
See MiNK Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$689.63 K |
| Cost of Revenue |
$181.75 K
|
$215.44 K
|
$204.62 K
|
$121.75 K
|
$77.96 K
|
$55.06 K
|
$0.00
|
| Gross Profit |
-$181.75 K
|
-$215.44 K
|
-$204.62 K
|
-$121.75 K
|
-$77.96 K
|
-$55.06 K
|
$689.63 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
| Research and Development Expenses |
$5.76 B
|
$6.34 M
|
$15.49 M
|
$23.12 M
|
$13.97 M
|
$9.51 M
|
$19.65 M
|
| General & Administrative Expenses |
$6.73 B
|
$4.31 B
|
$7.43 M
|
$0.00
|
$0.00
|
$0.00
|
$3.83 M
|
| Selling & Marketing Expenses |
$0.00
|
-$4.31 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$6.73 B
|
$4.10 M
|
$7.43 M
|
$7.71 M
|
$4.56 M
|
$1.23 M
|
$3.83 M
|
| Other Expenses |
-$12.47 B
|
$0.00
|
-$204.62 K
|
$0.00
|
$0.00
|
$0.00
|
-$508.07 K
|
| Operating Expenses |
$12.31 M
|
$10.43 M
|
$22.72 M
|
$30.83 M
|
$18.53 M
|
$10.74 M
|
$22.97 M
|
| Cost And Expenses |
$12.49 M
|
$10.65 M
|
$22.92 M
|
$30.95 M
|
$18.61 M
|
$10.80 M
|
$22.97 M
|
| Interest Income |
$180.25 K
|
$172.57 K
|
$463.26 K
|
$253.32 K
|
$2.43 K
|
$2.44 K
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$253.32 K
|
$2.43 M
|
$2.44 M
|
$1.56 M
|
| Depreciation & Amortization |
$181.75 K
|
$215.44 K
|
$204.62 K
|
$121.75 K
|
$77.96 K
|
$55.06 K
|
$36.82 K
|
| EBITDA |
-$12.31 M |
-$10.57 M |
-$22.25 M |
-$27.87 M |
-$27.70 M |
-$13.74 M |
-$22.20 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
-32.2
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
-32.31
|
| Total Other Income/Expenses Net |
-$6.96 K
|
-$134.56 K
|
$463.25 K
|
$2.96 M
|
-$11.61 M
|
-$5.44 M
|
-$1.52 M
|
| Income Before Tax |
-$12.49 M
|
-$10.78 M
|
-$22.46 M
|
-$27.99 M
|
-$30.21 M
|
-$16.24 M
|
-$23.80 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
-34.51
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$12.49 M
|
-$10.78 M
|
-$22.46 M
|
-$27.99 M
|
-$30.21 M
|
-$16.24 M
|
-$23.80 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
-34.51
|
| EPS |
-2.93 |
-2.9 |
-6.54 |
-8.31 |
-9.03 |
-4.91 |
-7.8 |
| EPS Diluted |
-2.93 |
-2.8 |
-6.54 |
-8.31 |
-9.03 |
-4.91 |
-10.8 |
| Weighted Average Shares Out |
$4.27 M
|
$3.74 M
|
$3.44 M
|
$3.37 M
|
$3.35 M
|
$3.31 M
|
$2.41 M
|
| Weighted Average Shares Out Diluted |
$4.27 M
|
$3.86 M
|
$3.44 M
|
$3.37 M
|
$3.35 M
|
$3.31 M
|
$2.41 M
|
| Link |
|
|
|
|
|
|
|
